首页> Blood: The Journal of the American Society of Hematology> Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens

Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens

导出原文传递

翻译打印收藏纠错

作者： Becnel, Melody R. ^[1] ; Rubin, M. Laura ^[2] ; Nair, Ranjit ^[3] ; Manasanch, Elisabet E. ; Lee, Hans C. ; Patel, Krina K. ; Iyer, Swaminathan P. ; Thomas, Sheeba K. ; Weber, Donna M. ; Orlowski, Robert Z.

作者单位： Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA ^[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA ^[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA ^[3]

发布时间 2020-08-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Blood

2018年Novel Treatment Appr期

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens

Blood

相似文献

Blood

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens

Blood

相似文献

Blood

相关期刊

检索历史清除